Visugromab plus standard chemo-immunotherapy for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an experimental drug called visugromab added to standard chemotherapy and immunotherapy for people newly diagnosed with advanced non-squamous lung cancer. It aims to see if the combination works better than standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer that has spread to other parts of the body (stage IV) and it has not been treated yet.
- Your tumor does not have a treatable gene change (like EGFR or ALK) that needs a targeted pill.
- You have not had immunotherapy or chemotherapy for this cancer before, but it's okay if you finished preventive treatment more than 12 months ago.
- You have a recent tumor biopsy that can be shared for research, and your PD-L1 level has been tested (if it's 50% or higher, immunotherapy alone is not right for you).
- You are 18 or older, able to do daily activities with little help (ECOG 0-1), and your organs (bone marrow, liver, kidneys, blood clotting) work well.
- You do not have active autoimmune disease, uncontrolled heart issues, lung scarring, or a recent heart attack or stroke.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (visugromab, nivolumab, and possibly docetaxel) for people with advanced non-squamous non-small cell lung cancer that worsened after one prior treatment with an immunotherapy. The goal is to see if the combination helps control the cancer better.
This trial tests a new treatment that uses a virus to attack cancer cells, combined with standard chemotherapy and an immunotherapy drug, for people with advanced non-small cell lung cancer that has gotten worse after initial treatment. The goal is to see if this combination works better than a different chemotherapy drug alone.
This trial tests a new investigational drug combined with chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. The goal is to see if it is safe and works better than current treatments.
This trial tests a combination of two drugs, vismodegib and atezolizumab, for people with non-small cell lung cancer that has spread or come back after standard treatments. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
This trial tests a new combination of two study medicines for people with advanced non-small cell lung cancer that has high levels of PD-L1 protein. The goal is to see if adding sigvotatug vedotin to pembrolizumab works better than pembrolizumab alone.
This Phase 2 trial studies pembrolizumab (an immune-boosting cancer medicine) alone or with an added investigational UV1 vaccine in people with advanced non-small cell lung cancer. It aims to see whether adding the vaccine improves safety and effectiveness, especially in tumors with high PD-L1 levels.
Hear when a new Metastatic Non-squamous Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.